

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 February 2020 (27.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/041541 A9

(51) International Patent Classification:
C07K 16/28 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2019/047607

(22) International Filing Date:
22 August 2019 (22.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/722,063 23 August 2018 (23.08.2018) US
62/734,130 20 September 2018 (20.09.2018) US
62/822,674 22 March 2019 (22.03.2019) US

(71) Applicant: SEATTLE GENETICS, INC. [US/US];
21823 30th Drive SE, Bothell, WA 98021 (US).

(72) Inventors: PIASECKI, Julia, C.; 21823 30th Drive SE,
Bothell, WA 98021 (US). BEERS, Courtney; 21823 30th
Drive SE, Bothell, WA 98021 (US). PETERSON, Scott;

21823 30th Drive SE, Bothell, WA 98021 (US). PRINZ,
Bianka; 7 Lucent Drive, Lebanon, NH 03766 (US). GAR-
DAI, Shyra; 21823 30th Drive SE, Bothell, WA 98021
(US).

(74) Agent: SCARR, Rebecca, B. et al.; McNeill Baur PLLC,
125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: ANTI-TIGIT ANTIBODIES




Fig. 1

(57) Abstract: Isolated antibodies that bind to human TIGIT (T-cell immunoreceptor with Ig and ITIM domains) are provided. In some embodiments, the antibody has a binding affinity (KD) for human TIGIT of less than 5 nM. In some embodiments, the anti-TIGIT antibody blocks binding of CD 155 and/or CD112 to TIGIT. In some embodiments, the antibodies are afucosylated.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

26 March 2020 (26.03.2020)

(48) Date of publication of this corrected version:

06 August 2020 (06.08.2020)

(15) Information about Correction:

see Notice of 06 August 2020 (06.08.2020)